WO2007077316A1 - Methode pour prevenir et/ou traiter des articles ou milieux contamines par des bacteries du genre legionella - Google Patents
Methode pour prevenir et/ou traiter des articles ou milieux contamines par des bacteries du genre legionella Download PDFInfo
- Publication number
- WO2007077316A1 WO2007077316A1 PCT/FR2006/002786 FR2006002786W WO2007077316A1 WO 2007077316 A1 WO2007077316 A1 WO 2007077316A1 FR 2006002786 W FR2006002786 W FR 2006002786W WO 2007077316 A1 WO2007077316 A1 WO 2007077316A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- legionella
- peptides
- seq
- peptide
- bacteria
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a method for preventing and / or treating articles, materials or surfaces, or media contaminated with Legionella bacteria. It also relates to the compositions used and the peptides active against these bacteria, hereinafter referred to as "anti-Legionella peptides". Bacteria of the genus Legionella belong to the family Legionellaceae. The genus Legionella is divided into 48 species with 70 distinct serogroups. The species Legionella pneumophila (L. pneumophila) is the bacterium responsible for legionellosis, a fatal pneumonia in about 15% of cases. This bacterium is mainly found in fresh and warm water.
- Biofilms are microbial communities adhering to a surface and frequently included in a matrix of extracellular polymers. Biofilms are present not only in nature but also in the human environment (pipes, medical devices ). Legionella can also be found in the free state or associated with amoebae, within which they develop. Amoebae are unicellular eukaryotes that belong to the family of protozoa. They play a crucial role in amplifying Legionella populations in aquatic systems, and protect them from adverse environmental conditions. They also provide them with a special environment that will promote their virulence vis-à-vis human cells.
- Thermal disinfection > 70 ° C
- the most common treatments are chemical treatments (chlorine and derivatives, oxidative treatments, metal ions ...) (Kim et al (2002), Water Res 36, 4433 - 4444).
- these treatments are not specifically targeted against Legioneila, which has the effect of disrupting the ecological balance of all microorganisms in the environment.
- the Legionella grow again, showing the limited effectiveness of the process.
- the chemicals used are an important source of pollution for the environment.
- Bacteriocins are anti-bacterial proteins or peptides produced by bacteria. They are produced by both Gram-negative and Gram-positive bacteria. They were first described in E. coli and called colicins. In Gram-positive bacteria, it is the bacteriocins produced by lactic acid bacteria that have been studied the most, given their potential use in agri-food and, more rarely, hygiene or health.
- US Patent 5,817,362 discloses a bacteriocin produced by Lactococcus lactis, which inhibits the development of a large number of bacteria such as Staphylococcus, Pediococcus, Lactococcus, Lactobacillus ... and which is used in the food field.
- US Patent 5,445,835 describes a method for producing a yoghurt comprising the bacteriocin PA-1.
- EP 927023 relates to a composition for treating acne, comprising a bacteriocin produced by Propionibacterium.
- EP 851751 relates to a chewing gum comprising as an antibacterial agent a bacteriocin.
- Application WO01 / 92533 relates to a Class IIa bacteriocin produced from a specific strain of Lactobacillus sakei, which proves particularly effective for inhibiting the growth of Listeria, and which can therefore be used industrially as an active agent against pathogenic or undesirable flora in the preparation of food products.
- the object of the invention is therefore the use of such peptides as anti-Legionella compounds.
- It also aims to provide a specifically targeted method of decontamination against Legionella bacteria, taking advantage of the properties of peptides isolated from compounds secreted by Staphylococcus and more particularly S. warneri.
- the invention also aims to provide a decontamination treatment method of Legionella without disturbing the ecological balance of the environment.
- the invention is further directed to the use of isolated active peptides for making drugs for the treatment of Legionella.
- the invention provides a method of treating a patient infected with Legionella with the help of said peptides.
- the invention therefore aims at the use of at least one peptide with an anti-legionella effect, for example in the test reported in the examples, the peptide or peptides being isolated and purified from the compounds secreted by Staphylococcus. , and more especially by S. warneri.
- anti-Legionella peptides are advantageously chosen from the group comprising amino acid sequence peptides SEQ ID No. 1:
- delta hemolysin 1 and delta hemolysin 2 isolated by purification from compounds secreted by S. warneri and responding, respectively, to the sequences SEQ ID No. 2 and SEQ ID NO: 3:
- SEQ ID NO: 2 MAADIISTIGDLVKLIINTVKKFQK
- SEQ ID NO: 3 MTADIISTIGDFVKWILDTVKKFTK.
- peptides may also be substituted and comprise, for example, a formyl substitution, it being understood that their substitution does not significantly affect the anti-Legionella activity as evaluated in the examples.
- the invention also relates to a method of preventing surfaces or materials likely to be in contact with bacteria of the genus Legionella and / or. decontamination of surfaces or materials infected with Legionella, this method comprising contacting the surface or the material to be treated with a composition containing an effective amount of at least one peptide as defined above.
- compositions used in the above applications are advantageously in the form of solutions or suspensions and optionally contain adjuvants facilitating the application and / or enhancing the activity of the peptides.
- the peptides used according to the invention exhibit activity against all bacteria of the genus Legionella. Conversely, they are not active against other non-Legionella bacteria.
- peptides are especially active against the bacteria of the genus Legionella selected from the group consisting of Legionella pneumophila, Legionella bozemanii, Legionella dumofii, Legionella longbeachae, Legionella micdadei, Legionella feeleii, Legionella hackeliae, Legionella sainthelensi, Legionella spietensis, Legionella erythra and Legionella species. quinlivanii.
- the subject of the present invention is also the use of a peptide (or peptides) as defined above for the preparation of a medicament intended to combat against legionellosis.
- the drug contains an amount of active ingredient to obtain the effect desired by the treatment and is in the appropriate forms of administration for example for treatment orally, parenterally, or by inhalation.
- tablets, tablets or capsules are used.
- Forms suitable for parenteral administration include sterile or sterilizable solutions or suspensions of said peptides.
- aerosols are advantageously used.
- the peptides of sequence SEQ ID No. 1 are new products and as such fall within the scope of the invention. They comprise the peptide SEQ ID No. 1 and substituted peptides as indicated above. Pharmaceutical compositions comprising a therapeutically effective amount of this peptide of sequence SEQ ID No. 1 or new anti-Legionella peptides as defined above in association with a pharmaceutically inert carrier are also covered by the invention.
- the invention is further directed to the transfer or expression vectors, in particular of the plasmid type, characterized in that they comprise at least one DNA fragment as defined above.
- FIGS. 1 to 4 represent, respectively:
- FIG. 1 the chromatogram obtained during HPLC of the seven fractions T15 to T21 obtained by solid phase extraction with an acetonitrile-TFA elution gradient starting at 20% of acetonitrile,
- FIG. 2 the mass spectrum of the active fraction T17
- FIG. 3 the results of the activity test in wells obtained with the fraction purified by HPLC.
- EXAMPLE 1 Isolation and Characterization of Legionella-active Peptides from the Staphylococcus Warneri Strain
- the bacterial strain Staphylococcus warneri named "RK” is isolated as indicated in the article by Inventors Héchard et al. (2005, FEMS Microbiol Lett., 252, 19-23).
- Peptide anW-Legionella SEQ ID No. 1 was purified by a method which differs from that described in the article of the inventors since it was not possible in the protocol described in Héchard et al. (2005, FEMS Microbiol Lett., 252, 19-23) to obtain a pure peptide and that only a mixture was obtained. This article therefore did not make it possible to provide that the peptide of the invention obtained by purification existed and that it was then possible to obtain a product of high efficiency exploitable industrially since pure.
- the strain of Staphylococcus warneri RK is cultured for 24 h in Brain Heart Infusion (BHI) medium (200 ml in a 1 L Erlenmeyer flask with stirring at 37 ° C). The culture is centrifuged (6000 g, 15 min, 4 ° C). The supernatant is stored and heated for 15 min at 70 ° C. This sample constitutes the crude extract.
- BHI Brain Heart Infusion
- the pH of the crude extract is brought to 5 with HCI hydrochloric acid solution.
- the solution (100 ml) is then passed through a cation exchange chromatographic column (Hiprep TM 16/10 Carboxy-Methyl FF, Amersham Biosciences), washed successively with 100 ml of sodium acetate buffer (20 mM, pH 5) at room temperature. 0, 0.1 and 1 M NaCl.
- the growth of L pneumophila is inhibited by the fraction eluted with 1 M sodium acetate NaCl.
- This fraction ( ⁇ 100 ml) is then loaded on a solid phase extraction cartridge (Sep-pak C18, Waters) previously washed and equilibrated (10 ml of ethanol, 5 ml of acetonitrile and 10 ml of water MiIIi -Q). The elution is carried out sequentially with 5 ml of increasingly concentrated solution of acetonitrile (0, 20, 40, 80 and 100%) and containing 0.05% of trifluoroacetic acid (TFA). The various fractions harvested are then concentrated and lyophilized to be finally suspended in 1 ml of sterile water, then tested against L pneumophila activity.
- a solid phase extraction cartridge Sep-pak C18, Waters
- Pneumophila is inhibited with the fraction containing 80% acetonitrile.
- the peptide is totally isolated. It has a high efficiency, exploitable industrially since pure.
- the elution is made from a linear gradient H 2 ⁇ -acetonitrile-TFA (0.05%) ranging from 20% to 100% acetonitrile and this in 45 min with the last 10 minutes at 100% of acetonitrile-TFA (flow rate: 0.8 ml.min -1 )
- Detection is carried out at 220 nm After evaporation of the acetonitrile and lyophilization, each of the fractions, T15 to T21, is suspended in 1 ml of water sterile, then tested in activity.
- a suspension of L ⁇ gionella pneumophila Lens is performed in 1 ml of sterile milli-Q water.
- the optical density (OD) at 600 nm with 1/10 th of the suspension is measured.
- Extract for spreading (which is done with a spreader).
- composition of the BCYE medium is as follows:
- Wells are made in BCYE agar using a cookie cutter. 100 ⁇ l of the test solution (T15 to T21) is deposited in a well. The dish is then incubated at 37 ° C. in the presence of 5% CO 2 for 72 hours.
- Electrospray ionization mass spectrometry analysis of the active fraction T17 made it possible to determine the mass of the corresponding peptide: 2561.04 Da (see FIG. 2).
- the antagonistic effect is responsible for a zone of inhibition of Legionella around the wells, the radius of which is proportional to the concentration of the bacteriocin.
- Figure 3 illustrates the test for anti-Le ⁇ // one // a well activity of purified T17 fraction in HPLC.
- T18 and T19 fractions showed that they were respectively delta hemolysins 1 and 2.
- the peptide of SEQ ID No. 1 sequence was also obtained by peptide synthesis (Eurogentec).
- the synthetic peptide has the same properties as the peptide from the bacterial strain: same retention time in HPLC, same mass spectrum and identical activity.
- EXAMPLE 2 Isolation and Characterization of Delta Hemolysins 1 and 2 from the S. warneri strain
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/086,915 US20100168001A1 (en) | 2005-12-20 | 2006-12-19 | Method for Preventing and/or Treating Articles or Media Contaminated With Bacteria of the Legionelle Genus |
CA002632918A CA2632918A1 (fr) | 2005-12-20 | 2006-12-19 | Methode pour prevenir et/ou traiter des articles ou milieux contamines par des bacteries du genre legionella |
EP06847069A EP1966380A1 (fr) | 2005-12-20 | 2006-12-19 | Methode pour prevenir et/ou traiter des articles ou milieux contamines par des bacteries du genre legionella |
AU2006334313A AU2006334313A1 (en) | 2005-12-20 | 2006-12-19 | Method for preventing and/or treating articles or media contaminated with bacteria of the legionella genus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR05/12955 | 2005-12-20 | ||
FR0512955A FR2894969B1 (fr) | 2005-12-20 | 2005-12-20 | Peptides actifs contre les bacteries du genre legionella |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007077316A1 true WO2007077316A1 (fr) | 2007-07-12 |
Family
ID=36646051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2006/002786 WO2007077316A1 (fr) | 2005-12-20 | 2006-12-19 | Methode pour prevenir et/ou traiter des articles ou milieux contamines par des bacteries du genre legionella |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100168001A1 (fr) |
EP (1) | EP1966380A1 (fr) |
AU (1) | AU2006334313A1 (fr) |
CA (1) | CA2632918A1 (fr) |
FR (1) | FR2894969B1 (fr) |
WO (1) | WO2007077316A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012168908A1 (fr) | 2011-06-10 | 2012-12-13 | Centre National De La Recherche Scientifique (Cnrs) | Peptides pour leur utilisation dans le traitement du cancer |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8609110B2 (en) | 2011-06-21 | 2013-12-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Citrobacter freundii antibacterial agents and their use |
FR3026917B1 (fr) * | 2014-10-08 | 2018-03-02 | Centre National De La Recherche Scientifique (Cnrs) | Biosurfactants de pseudomonas pour lutter contre les legionelles |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998036084A2 (fr) * | 1997-02-14 | 1998-08-20 | Agricola Technologies, Inc. | Amelioration de la croissance des vegetaux a l'aide de genes codant pour une anhydrase carbonique, une proteine fixant le calcium, une proteine fixant un metal, ou une proteine de biomineralisation |
-
2005
- 2005-12-20 FR FR0512955A patent/FR2894969B1/fr not_active Expired - Fee Related
-
2006
- 2006-12-19 US US12/086,915 patent/US20100168001A1/en not_active Abandoned
- 2006-12-19 WO PCT/FR2006/002786 patent/WO2007077316A1/fr active Application Filing
- 2006-12-19 EP EP06847069A patent/EP1966380A1/fr not_active Withdrawn
- 2006-12-19 CA CA002632918A patent/CA2632918A1/fr not_active Abandoned
- 2006-12-19 AU AU2006334313A patent/AU2006334313A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998036084A2 (fr) * | 1997-02-14 | 1998-08-20 | Agricola Technologies, Inc. | Amelioration de la croissance des vegetaux a l'aide de genes codant pour une anhydrase carbonique, une proteine fixant le calcium, une proteine fixant un metal, ou une proteine de biomineralisation |
Non-Patent Citations (3)
Title |
---|
HECHARD ET AL: "Isolation and characterization of a Staphylococcus warneri strain producing an anti-Legionella peptide", FEMS MICROBIOLOGY LETTERS, AMSTERDAM, NL, vol. 252, no. 1, 1 November 2005 (2005-11-01), pages 19 - 23, XP005146513, ISSN: 0378-1097 * |
KREGER A S ET AL: "PURIFICATION AND PROPERTIES OF STAPHYLOCOCCAL DELTA HEMO LYSIN", INFECTION AND IMMUNITY, vol. 3, no. 3, 1971, pages 449 - 465, XP002432722, ISSN: 0019-9567 * |
TEGMARK KARIN ET AL: "Regulation of agr-dependent virulence genes in Staphylococcus aureus by RNAIII from coagulase-negative staphylococci", JOURNAL OF BACTERIOLOGY, vol. 180, no. 12, June 1998 (1998-06-01), pages 3181 - 3186, XP002432721, ISSN: 0021-9193 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012168908A1 (fr) | 2011-06-10 | 2012-12-13 | Centre National De La Recherche Scientifique (Cnrs) | Peptides pour leur utilisation dans le traitement du cancer |
FR2976180A1 (fr) * | 2011-06-10 | 2012-12-14 | Centre Nat Rech Scient | Peptides pour leur utilisation dans le traitement du cancer |
Also Published As
Publication number | Publication date |
---|---|
US20100168001A1 (en) | 2010-07-01 |
AU2006334313A1 (en) | 2007-07-12 |
FR2894969A1 (fr) | 2007-06-22 |
FR2894969B1 (fr) | 2008-02-22 |
EP1966380A1 (fr) | 2008-09-10 |
CA2632918A1 (fr) | 2007-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hegstad et al. | Does the wide use of quaternary ammonium compounds enhance the selection and spread of antimicrobial resistance and thus threaten our health? | |
CN107735098B (zh) | 抗微生物疗法 | |
AU2004275696B2 (en) | Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation | |
Schroll et al. | Role of type 1 and type 3 fimbriae in Klebsiella pneumoniae biofilm formation | |
JP2009538614A5 (fr) | ||
JP5647137B2 (ja) | 新規のポリアミノポリケチド抗生物質およびその使用 | |
Duraisamy et al. | Bacteriocin—a potential antimicrobial peptide towards disrupting and preventing biofilm formation in the clinical and environmental locales | |
US11649267B2 (en) | Mitrecin A polypeptide with antimicrobial activity | |
US20080075730A1 (en) | Methods and compositions for treating biofilms | |
Xu et al. | Comparative study on inhibitory effects of ferulic acid and p-coumaric acid on Salmonella Enteritidis biofilm formation | |
Ma et al. | Antibiofilm activity and modes of action of a novel β-sheet peptide against multidrug-resistant Salmonella enterica | |
WO2012017434A2 (fr) | Composés destinés au traitement d'infections bactériennes | |
WO2007077316A1 (fr) | Methode pour prevenir et/ou traiter des articles ou milieux contamines par des bacteries du genre legionella | |
RU2668160C1 (ru) | Антибактериальная композиция, содержащая белок adk в качестве активного ингредиента, для борьбы с карбапенем-резистентными грамотрицательными бактериями | |
Nde et al. | Global transcriptomic response of Pseudomonas aeruginosa to chlorhexidine diacetate | |
WO2019126480A1 (fr) | Procédés de régulation d'infection en utilisant des inhibiteurs de croissance de petite molécule de nouvelle génération | |
EP3658174B1 (fr) | Lactoferricine et lactoferrampine pour traiter les infections | |
Sadaqat et al. | Curcumin carbon dots inhibit biofilm formation and expression of esp and gelE genes of Enterococcus faecium | |
AU2017296061A9 (en) | Lantibiotic variants and uses thereof | |
Jolivet‐Gougeon et al. | Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved | |
Gudata et al. | Antimicrobial resistance | |
CA2972079A1 (fr) | Un antibacterien inorganique synthetique potent ayant une activite contre les pathogenes resistants aux medicaments | |
TW200806688A (en) | Peptide compound with biological activity, its preparation and its applications | |
Rasheed et al. | Impact of Cu (II)-doping on the vulnerability of Escherichia coli ATCC 10536 revealed by Atomic Force Microscopy | |
Adkin | Understanding Bacterial Resistance and Dissemination: The Impact of Biocide Priming |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006847069 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2632918 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006334313 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006334313 Country of ref document: AU Date of ref document: 20061219 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006334313 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12086915 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2006847069 Country of ref document: EP |